In short
Clinical trials are studying Rosnilimab in people with moderate to severe rheumatoid arthritis and ulcerative colitis. These studies aim to see whether Rosnilimab is safe and effective compared with placebo. Both trials are phase 2 and have already been completed.
Key points
- Rosnilimab has been studied in two completed phase 2 clinical trials. One trial looked at people with moderate to severe rheumatoid arthritis, and the other studied people with ulcerative colitis. Both trials compared Rosnilimab with placebo to see whether it could improve disease activity. The rheumatoid arthritis study measured DAS28-CRP at week 12, while the ulcerative colitis study measured mMS at week 12. Together, these studies focused on adults with active, moderate to severe inflammatory disease.
Trial overview
Two clinical trials have studied Rosnilimab, and both were Phase 2 studies. Both trials were interventional, which means researchers gave a study treatment and measured the results. Both studies are listed as completed.
Rheumatoid arthritis study
One study tested Rosnilimab in people with moderate to severe rheumatoid arthritis, a disease that causes joint inflammation and pain. This trial enrolled 420 participants. The study title says it was randomized, double blind, and placebo controlled, which are trial methods used to make the comparison fair and reduce bias.
The main efficacy endpoint, or main result the study wanted to measure, was the mean change from baseline in DAS28-CRP at week 12. DAS28-CRP is a score used to track rheumatoid arthritis disease activity, and baseline means the starting point before treatment began.
Ulcerative colitis study
The second study looked at Rosnilimab in people with ulcerative colitis, a long-term inflammatory disease of the large intestine. This trial enrolled 132 participants. Like the rheumatoid arthritis study, it was a phase 2 interventional trial and was completed.
This study also compared Rosnilimab with placebo, meaning a look-alike treatment without the active study drug. Its primary efficacy endpoint was the mean change from baseline in mMS at week 12. The source data does not define mMS, but it is the main measure the study used to judge whether treatment helped.
Study design and comparators
Both Rosnilimab trials used a placebo-controlled design, which helps researchers see whether changes are due to the study treatment rather than chance or expectations. The rheumatoid arthritis trial was also described as double blind, meaning participants and study staff did not know which treatment each person received during the study.
The interventions listed in the source data include Rosnilimab given by subcutaneous use, which means under the skin, and matching placebo or matching solution for injection. This kind of matching treatment helps keep the study fair because the comparison groups look similar.
Outcomes measured
The main outcome in the rheumatoid arthritis trial was change in DAS28-CRP from baseline to week 12. This tells researchers whether disease activity improved over time.
The main outcome in the ulcerative colitis trial was change in mMS from baseline to week 12. This means the study focused on whether the disease score changed after 12 weeks of treatment.
What these trials mean for patients
These studies show that Rosnilimab was tested in two different inflammatory diseases, both with moderate to severe illness. The trials were designed to look for early signs of benefit and to continue safety checking in phase 2. Because both studies are completed, the trial records reflect research that has already been carried out rather than ongoing enrollment.